Scientist examining results

Targeted sequencing with Oncomine NGS oncology assays

Oncomine™ assays are multi-biomarker targeted assays designed for cancer research. Enabling next-generation sequencing analysis of multiple biomarker types—fusions, insertion/deletions (indels), single nucleotide variants, and copy number variations—Oncomine assays are part of an end-to-end workflow that includes simple, scalable sequencing with Ion GeneStudio S5 series sequencers, and optimized bioinformatics and reporting with the Oncomine™ Reporter.

Whether you are working with DNA or RNA, formalin-fixed, paraffin-embedded (FFPE) tissue samples, or blood, Oncomine assays engender trust among clinical cancer researchers because:

  • Content includes cancer genes and is reviewed by experienced professionals to help ensure the highest relevancy
  • Protocols and verification are based on analyses of clinical research samples to help ensure repeatable results
  • Assays are produced under enhanced manufacturing quality control to facilitate consistent analyses across large sample sets
  • Specialized application support teams are available to help enable faster implementation in your lab


Targeted NGS performance of Oncomine Assays and NCI-MATCH Trial Assay

The Oncomine Comprehensive Assay and NCI-MATCH Trial Assay* (based on the Oncomine Comprehensive Assay) have demonstrated robust performance even with very limited FFPE samples such as fine needle aspirates (FNA). Performance was evaluated through measures of reliability, sensitivity, specificity, and limit of detection.

See the data ›

Oncomine assays

Designed for concurrent DNA and RNA NGS analysis from FFPE samples. Targets 52 genes relevant to solid tumors. Detects SNVs, indels, CNVs, and fusions.

Designed for concurrent DNA and RNA NGS analysis from FFPE samples. Targets 143 cancer genes relevant to clinical cancer research. Detects SNVs, indels, CNVs, and fusions.

Tumor type-specific assays designed for NGS analysis from cell-free DNA and cell-free RNA.  Target genes relevant to lung, colon, and breast tumor samples.  Detect SNVs, indels, CNVs, and fusions, all from a single tube of blood.

Enables the detection of BRCA1/2 somatic mutations in FFPE tissue and germline mutations in whole blood

Gene expression assay designed for superior performance in the detection of low-expressing genes from minimal FFPE RNA input. Targets 395 genes associated with immune response biomarker research.

Interrogates relevant DNA mutations and fusion transcripts associated with myeloid disorders in a quick and easy NGS run

A robust, targeted NGS assay providing clinical researchers with an accurate quantification of somatic mutation counts to assess tumor mutation load with very limited FFPE samples

Advantages of the Oncomine NGS oncology workflow—because you need answers for every sample

With Ion Torrent™ next-generation sequencing (NGS) systems, you can analyze your sample for hundreds of variants of interest using a single sample in a single experiment. You can detect hotspots, SNVs, indels, CNVs, and gene fusions in a single run. For FFPE samples and liquid biopsy samples, both Ion AmpliSeq™ technology and Tag Sequencing technology enable results from as little as 1 ng of sample input.

With Ion Torrent NGS systems and Oncomine assays, your lab has the flexibility to scale and automate analyses to meet your sampling needs. Coupled with the Ion Chef™ System and the Ion S5 System, the Oncomine™ Focus Assay enables sample to refined variant data in as little as two days. And this same easy-to-use workflow achieves automated speed and simplicity to enable your lab technicians to run samples consistently. 


Using NGS data to help inform therapy selection

Dr. Giselle Sholler

Pediatric cancers are challenging because their origins differ from adult cancers, and because historically many of the tools used to study adult cancers have not been adapted for pediatric studies.

That is changing. Pediatric oncologists are not only working with NGS data, they are seeking it out, helping drive the future of pediatric cancer care.

Watch the video ›